CureVac GmbH, developer of a novel messenger RNA vaccine technology, has obtained €80 million in new financing from its principal shareholder, dievini Hopp Biotech Holding, enabling it to advance the clinical development of its lead product – a therapeutic vaccine for prostate cancer.
